scholarly journals 18F-Deoxyglucose Positron Emission Tomography/Computed Tomography in Multiple Myeloma

2021 ◽  
Vol 3 (4) ◽  
pp. 20
Author(s):  
Su Liu ◽  
YaFei Wang
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Multiple Myeloma ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma

Molecules ◽  
2019 ◽  
Vol 25 (1) ◽  
pp. 134 ◽  
Author(s):  
Christos Sachpekidis ◽  
Hartmut Goldschmidt ◽  
Antonia Dimitrakopoulou-Strauss
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Disease ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg

Multiple myeloma (MM) is a plasma cell disorder, characterized by clonal proliferation of malignant plasma cells in the bone marrow. Bone disease is the most frequent feature and an end-organ defining indicator of MM. In this context, imaging plays a pivotal role in the management of the malignancy. For several decades whole-body X-ray survey (WBXR) has been applied for the diagnosis and staging of bone disease in MM. However, the serious drawbacks of WBXR have led to its gradual replacement from novel imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT). PET/CT, with the tracer 18F-fluorodeoxyglucose (18F-FDG), is now considered a powerful diagnostic tool for the detection of medullary and extramedullary disease at the time of diagnosis, a reliable predictor of survival as well as the most robust modality for treatment response evaluation in MM. On the other hand, 18F-FDG carries its own limitations as a radiopharmaceutical, including a rather poor sensitivity for the detection of diffuse bone marrow infiltration, a relatively low specificity, and the lack of widely applied, established criteria for image interpretation. This has led to the development of several alternative PET tracers, some of which with promising results regarding MM detection. The aim of this review article is to outline the major applications of PET/CT with different radiopharmaceuticals in the clinical practice of MM.

scholarly journals Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study

2017 ◽  
Vol 35 (25) ◽  
pp. 2911-2918 ◽  
Author(s):  
Philippe Moreau ◽  
Michel Attal ◽  
Denis Caillot ◽  
Margaret Macro ◽  
Lionel Karlin ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Multiple Myeloma ◽  
Emission Tomography ◽  
Bone Lesions ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Pet Ct ◽  
Ct And Mri

Purpose Magnetic resonance imaging (MRI) and positron emission tomography–computed tomography (PET-CT) are important imaging techniques in multiple myeloma (MM). We conducted a prospective trial in patients with MM aimed at comparing MRI and PET-CT with respect to the detection of bone lesions at diagnosis and the prognostic value of the techniques. Patients and Methods One hundred thirty-four patients received a combination of lenalidomide, bortezomib, and dexamethasone (RVD) with or without autologous stem-cell transplantation, followed by lenalidomide maintenance. PET-CT and MRI were performed at diagnosis, after three cycles of RVD, and before maintenance therapy. The primary end point was the detection of bone lesions at diagnosis by MRI versus PET-CT. Secondary end points included the prognostic impact of MRI and PET-CT regarding progression-free (PFS) and overall survival (OS). Results At diagnosis, MRI results were positive in 127 of 134 patients (95%), and PET-CT results were positive in 122 of 134 patients (91%; P = .33). Normalization of MRI after three cycles of RVD and before maintenance was not predictive of PFS or OS. PET-CT became normal after three cycles of RVD in 32% of the patients with a positive evaluation at baseline, and PFS was improved in this group (30-month PFS, 78.7% v 56.8%, respectively). PET-CT normalization before maintenance was described in 62% of the patients who were positive at baseline. This was associated with better PFS and OS. Extramedullary disease at diagnosis was an independent prognostic factor for PFS and OS, whereas PET-CT normalization before maintenance was an independent prognostic factor for PFS. Conclusion There is no difference in the detection of bone lesions at diagnosis when comparing PET-CT and MRI. PET-CT is a powerful tool to evaluate the prognosis of de novo myeloma.

scholarly journals IMAGING TECHNIQUES USED IN MULTIPLE MYELOMA

2015 ◽  
Vol 1 (1) ◽  
Author(s):  
Abdul Hameed ◽  
Paul Foran ◽  
Peter O'Gorman ◽  
Jonathan Ryan
Keyword(s):  
Magnetic Resonance Imaging ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Multiple Myeloma ◽  
Magnetic Resonance ◽  
Imaging Techniques ◽  
Skeletal Survey ◽  
Emission Tomography ◽  
Resonance Imaging ◽  
Positron Emission

Multiple myeloma (MM) is a plasma cell disorder, characterised by bone marrow infiltration with clonal plasma cells; production of monoclonal immunoglobulin (paraprotein); end-organ damage; lytic lesions in the bones; renal impairment; hypercalcaemia and anaemia. Skeleton evaluation in MM is necessary not only for staging purposes but also to detect serious complications such as fractures. Skeletal survey is an established rst-line investigation for this purpose. However, in recent years, new imaging techniques such as whole-body magnetic resonance imaging and 2- uoro-2-deoxy-D-glucose positron emission tomography computed tomography have been used widely. In this article, we review different imaging techniques used in MM and their impact on patient management. Key words: Imaging techniques, magnetic resonance imaging, multiple myeloma, osteolytic lesions, positron emission tomography/computed tomography, skeletal survey 

Sign in / Sign up

Export Citation Format

Share Document